LENZ

Pomerantz LLP is investigating potential securities fraud claims against LENZ Therapeutics following disappointing Q2 2026 earnings. The company reported flat organic product sales of $1.73 million for its primary eye drop VIZZ, with most revenue ($3.8M of $5.5M total) coming from one-time licensing milestones. Bank of America subsequently downgraded the stock from 'Buy' to 'Neutral' and slashed its price target from $31 to $7, citing slower-than-expected commercial launch performance.

Regeneron is expected to report Q3 2026 earnings of $16.08 per share (up 35.9% YoY) and revenues of $4.55 billion (up 21.2% YoY) on October 30. However, the company's Earnings ESP is -1.12%, indicating recent analyst bearishness, making it difficult to predict an earnings beat despite its Zacks Rank #3 rating. The company has a strong history of beating estimates, having surpassed consensus four times in the last four quarters.